Nanobody Yeast Display Development Services
IMMUNE Platform Introduction
IMMUNE (Identifying Massive MHC Utilized Novel Epitopes) platform, developed by JWE, is a proprietary immune epitope analysis platform designed for the development and screening of TCR-like antibodies. It is based on a yeast-displayed HLA system enabling efficient epitope identification and analysis.
| Platform Name |
IMMUNE Platform |
| Platform Type |
Proprietary immune epitope discovery and analysis platform |
| Platform ID |
JWEPFM0001 |
Core Technical Strategies
| Technical Strategy |
Description |
| Yeast-displayed HLA Technology |
Displays HLA molecules on yeast surface without HLA purification or complex cell culture |
| Functional “Empty” HLA Display |
Ensures specificity of epitope recognition |
| Single-allele HLA Peptide Exchange |
Avoids cross-reactivity interference |
| Concentration-dependent Competitive Assay |
Quantitatively measures HLA-peptide binding affinity |
| Broad Applicability |
Supports classical and non-classical HLA analysis while maintaining native conformation |
Application Areas
| Application |
Examples |
| Epitope Validation and Analysis |
HLA complex verification, peptide analysis, TCR epitope evaluation |
| Vaccine Development |
Tumor neoantigen mRNA/peptide vaccine evaluation, HLA-specific viral mRNA/peptide vaccine assessment |
| Immune Target Discovery |
Evaluation of tumor, autoimmune, and infectious pathogen HLA-restricted antigen targets |
| Immunotherapeutic Development |
Assessment of HLA-peptide-specific TCR/TCRL/TCRm |
| Binding Protein Analysis |
Study interactions of HLA-binding proteins (CD4, CD8, HLA-specific antibodies, superantigens, viral entry proteins, etc.) |
Platform Overview
Based on Yeast Surface Display (YSD), enables high-throughput screening and affinity clustering of nanobodies (VHH). Library capacity reaches 108 with diversity, insertion rate, and positivity rate all exceeding 90%, meeting high standards for research and drug development.
Technical Principle
VHH antibody genes are fused with yeast surface protein Aga2p via PCR. Aga2p binds through disulfide bonds to Aga1p anchored on the yeast cell wall. Using FACS (Fluorescence-Activated Cell Sorting), nanobodies with specific target binding can be efficiently identified and clustered.
Service Contents & Timeline
| Step |
Service Content |
Timeline |
| Library Construction |
High-fidelity PCR amplification of VHH genes and cloning into yeast display vectors to construct antibody libraries with high insertion and library capacity. |
2-3 weeks |
| Library Screening |
Screen specific antibodies using fluorescently labeled proteins and FACS. Cluster by affinity and validate single-clone expression. |
3-4 weeks |
| Antibody Validation |
Recombinant antibody expression, affinity purification, and quantification. ELISA/BLI validate binding and affinity. |
4-6 weeks |
Library Information
| Library Type |
Capacity |
Insertion Rate |
Positivity Rate |
| VHH Nanobody Library |
108 |
90%+ |
90%+ |
| scFv Antibody Library |
107-108 |
85%+ |
85%+ |
Antibody Target Types
| Target Type |
Examples |
| Recombinant Proteins |
Membrane proteins, enzymes, signaling molecules |
| Peptides/Small Molecules |
Antigen peptides, small molecule drugs |
| Viruses/Nucleic Acids |
Inactivated viruses, mRNA |
Service Advantages
- No animal immunization required, reducing ethical concerns and experimental complexity
- High library diversity with insertion and positivity rates over 90%
- FACS allows clustering of antibodies with different affinities
- Customizable services to meet research and drug development needs
- Combined with IMMUNE Platform, enables qualitative and quantitative analysis of HLA-peptide binding
Back to Services
